Qiagen Expands Its Protein Analysis Play With Two More Buys; Eyes Dx Applications | GenomeWeb

Continuing its push into the protein analysis market, Qiagen will spend up to $17.6 million to acquire the assets of LumiCyte and the entire bioanalytical business of SuNyx.

Both companies make products for peptide and protein sample preparation that run on mass spectrometry instrumentation and will provide Qiagen with two more platforms for its rapidly emerging protein-analysis business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.